Poor Sleep and Daytime Somnolence in Allergic Rhinitis

2002 ◽  
Vol 1 (3) ◽  
pp. 195-200 ◽  
Author(s):  
Sujani Kakumanu ◽  
Casey Glass ◽  
Timothy Craig
Keyword(s):  
Allergic Rhinitis ◽  
Poor Sleep ◽  
Daytime Somnolence

scholarly journals 342 The Association Between Benzodiazepine Use and Falls, and the Impact of Sleep Quality on this Association: Data from TILDA

2019 ◽  
Vol 48 (Supplement_3) ◽  
pp. iii17-iii65
Author(s):  
Louise Marron ◽  
Ricardo Segurado ◽  
Paul Claffey ◽  
Rose Anne Kenny ◽  
Triona McNicholas
Keyword(s):  
Older Adults ◽  
Sleep Quality ◽  
Effect Size ◽  
Community Dwelling ◽  
Public Health Issue ◽  
P Value ◽  
Poor Sleep ◽  
Daytime Somnolence ◽  
Falling Asleep ◽  
The Impact

Abstract Background Benzodiazepines (BZD) are associated with adverse effects, particularly in older adults. Previous research has shown an association between BZDs and falls and BZDs have been shown to impact sleep quality. The aim of this study is to assess the association between BZD use and falls, and the impact of sleep quality on this association, in community dwelling adults aged over 50. Methods Data from the first wave of The Irish Longitudinal Study on Ageing were used. Participants were classed as BZD users or non-users and asked if they had fallen in the last year, and whether any of these falls were unexplained. Sleep quality was assessed via self-reported trouble falling asleep, daytime somnolence, and early-rising. Logistic regression assessed for an association between BZD use and falls, and the impact of sleep quality on this association was assessed by categorising based on BZD use and each sleep quality variable. Results Of 8,175 individuals, 302 (3.69%) reported taking BZDs. BZD use was associated with falls, controlling for con-founders (OR 1.40; 1.08, 1.82; p-value 0.012). There was no significant association between BZDs and unexplained falls, controlling for con-founders (OR 1.41; 95% CI 0.95, 2.10; p-value 0.09), however a similar effect size to all falls was evident. Participants who take BZDs and report daytime somnolence (OR 1.93; 95% CI 1.12, 3.31; p-value 0.017), early-rising (OR 1.93; 95% CI 1.20, 3.11; p-value 0.007) or trouble falling asleep (OR 1.83; 95% CI 1.12, 2.97; p-value 0.015), have an increased odds of unexplained falls. Conclusion BZD use is associated with falls, with larger effect size in BZD users reporting poor sleep quality in community dwelling older adults. Appropriate prescription of and regular review of medications such as BZDs is an important public health issue.

scholarly journals Screening Commercial Vehicle Drivers for Obstructive Sleep Apnea: Tools, Barriers, and Recommendations

2017 ◽  
Vol 65 (10) ◽  
pp. 487-492 ◽  
Author(s):  
Kelly A. Evans ◽  
Tracey Yap ◽  
Barbara Turner
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Commercial Vehicle ◽  
Crash Risk ◽  
Poor Sleep ◽  
Daytime Somnolence ◽  
Sleep Study ◽  
Awareness Campaigns ◽  
Obstructive Sleep ◽  
Commercial Drivers

Obstructive sleep apnea (OSA) is a disorder characterized by a cessation of breathing during sleep, leading to poor sleep patterns and daytime somnolence. Daytime somnolence is of particular concern for commercial vehicle drivers, whose crash risk increases 50% with untreated OSA. The process of diagnosing and treating OSA in commercial drivers begins with effective and consistent screening. Therefore, the researchers screened drivers with both the STOP-Bang Questionnaire and the Obstructive Sleep Apnea Evaluation Worksheet (OSAEW) and compared the two tools. Drivers screening positive on the STOP-Bang Questionnaire, OSAEW, and both questionnaires were 28%, 23%, and 13%, respectively. Sleep study referrals were made for 50 drivers; 12 drivers were scheduled for sleep tests within 3 months. Health care provider referral rates for drivers screening at high risk (37%) and commercial driver monitoring rates (24%) were both low. Recommendations to improve OSA screening and testing practices include Federal Motor Carrier Safety Administration–mandated screening and referral guidelines, employee-facilitated sleep testing, and OSA awareness campaigns.

The role of pseudoephedrine on daytime somnolence in patients suffering from perennial allergic rhinitis (PAR)

2011 ◽  
Vol 106 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Amir A. Sherkat ◽  
Niti Sardana ◽  
Sahar Safaee ◽  
Erik B. Lehman ◽  
Timothy J. Craig
Keyword(s):  
Allergic Rhinitis ◽  
Daytime Somnolence ◽  
Perennial Allergic Rhinitis

Chronisch-obstruktive Lungenerkrankung: Verbesserung von Schlaf und Tagesmüdigkeit durch pneumologische Rehabilitation

2020 ◽  
Vol 8 (4) ◽  
pp. 200-201
Author(s):  
Guzel Gafina ◽  
Marc Spielmanns
Keyword(s):  
Sleep Quality ◽  
Pulmonary Rehabilitation ◽  
Rehabilitation Program ◽  
Chronic Obstructive ◽  
Poor Sleep ◽  
Daytime Somnolence ◽  
Poor Sleep Quality ◽  
Subjective Sleep Quality ◽  
Copd Patients ◽  
Pulmonary Rehabilitation Program

Background: Dyspnea, fatigue, and decline in sleep quality are symptoms of chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation programs have been shown to ameliorate dyspnea and fatigue. However, only a few studies have investigated the effects of pulmonary rehabilitation on the sleep quality of COPD patients. In this study, we analyzed the benefits of a pulmonary rehabilitation program to sleep quality and daytime somnolence in COPD patients. Methods: This study was a study of 30 moderate-severe COPD patients. All patients were evaluated by a pulmonologist and underwent polysomnography before participating in the study. For this study, we selected only ex-smokers and patients with sleep apnea were referred to the sleep clinic. These participants were prospectively recruited and not selected based on program completion. Before the start of the program, sleep quality and daytime somnolence of the participants were evaluated using the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS), respectively. Rehabilitation program consisted of muscular training sessions conducted at the gym 3 times per week for 12 weeks. After rehabilitation program, the patients were reassessed and their sleep quality and daytime somnolence were reevaluated using the PSQI and the ESS, respectively. Results: Before rehabilitation, PSQI evaluation revealed that 73% of the participants had poor sleep quality, and ESS evaluation showed that 86.7% of the participants experienced daytime somnolence. After pulmonary rehabilitation, the PSQI specifically improved in terms of subjective sleep quality and sleep duration (< 0.001), habitual sleep efficiency (0.001), and sleep latency and sleep alterations (0.002) and there was also improvement in the ESS (< 0.001). Conclusion: Pulmonary rehabilitation program of gradually increasing intensity has the potential to provide sleep-related benefits to patients with COPD who have poor sleep quality and daytime somnolence. Trial registration: Registro Brasileiro de Ensaios Clínicos (ReBEC) RBR62b4z2.

scholarly journals CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria

2019 ◽  
Vol 15 (1) ◽  
Author(s):  
Michael N. Fein ◽  
David A. Fischer ◽  
Andrew W. O’Keefe ◽  
Gord L. Sussman
Keyword(s):  
Allergic Rhinitis ◽  
Chronic Urticaria ◽  
First Generation ◽  
Position Statement ◽  
Poor Sleep ◽  
Third Generation ◽  
First Line ◽  
H1 Antihistamines ◽  
History Of ◽  
History Of Use

Abstract Oral H1-antihistamines (AHs) are the most commonly used therapy to treat allergic rhinitis and chronic urticaria. Older, first-generation AHs (e.g. diphenhydramine, hydroxyzine) have significant and common side effects including sedation, impairment with decreased cognitive function, poor sleep quality, dry mouth, dizziness, and orthostatic hypotension. These drugs have also been found to result in death from accidents, intentional or unintentional overdoses, and sudden cardiac death. The unfavourable risk–benefit profile of first-generation AHs led to the development of newer, less-sedating second- and third-generation AHs, which first became available in Canada in the 1980s. High-quality trials have proven that newer generation AHs are superior in safety compared to older first-generation AHs. On average, they have improved potency and efficacy. Second- and third-generation AHs are the recommended first-line treatment for mild allergic rhinitis and acute and chronic urticaria. Despite this evidence, older first-generation AHs continue to be over-utilized because of their over-the-counter (OTC) status and long history of use. The Canadian Society of Allergy Clinical Immunology (CSACI) recommends that newer generation AHs should be preferred over first-generation AHs for the treatment of allergic rhino-conjunctivitis and urticaria. To promote this recommendation, education of health professionals and the public is necessary. Further, given the dangers of older first-generation AHs, we believe they should be used only as a last resort with eventual consideration given to having them only available behind the counter in pharmacies.

The role of montelukast on perennial allergic rhinitis and associated sleep disturbances and daytime somnolence

2008 ◽  
Vol 29 (2) ◽  
pp. 140-145 ◽  
Author(s):  
Carah B. Santos ◽  
Christopher Hanks ◽  
Jeffrey McCann ◽  
Erik B. Lehman ◽  
Ellen Pratt ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Sleep Disturbances ◽  
Daytime Somnolence ◽  
Perennial Allergic Rhinitis
Sign in / Sign up

Export Citation Format

Share Document